Alogliptin (Vipidia®)

Assessment Status Rapid Review Complete
Drug Alogliptin
Brand Vipidia®
Indication For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Assessment Process
Rapid review commissioned 27/09/2013
Rapid review completed 30/10/2013
Rapid review outcome Full HTA not recommended